PolyPid Ltd. Q3 2025 Earnings Recap

PYPD Q3 2025 November 12, 2025

Get alerts when PYPD reports next quarter

PolyPid Ltd. reported significant progress in Q3 2025, highlighted by a scheduled pre-NDA meeting with the FDA for DPLEX 100, a system aimed at preventing surgical site infections, positioning the company for key commercial milestones ahead.

Earnings Per Share Beat

$-0.37 vs $-0.54 est.

+31.5% surprise

Market Reaction

1-Day -0.27%

5-Day -3.32%

30-Day +5.59%

See PYPD alongside your other holdings

Add to your portfolio — free

Key Takeaways

Scheduled pre-NDA meeting with the FDA for DPLEX 100 in early December is a critical step towards market introduction.
Positive results from a new market access study indicate strong demand for DPLEX 100 among surgeons and hospital pharmacy directors.
Successful completion of GMP inspection supports the company’s manufacturing readiness for both the US and European markets.
Ongoing strategic discussions with potential US partners enhance the commercial outlook leveraging strong Phase III trial results.
PolyPid is advancing its pipeline, indicating future growth opportunities in oncology, obesity, and diabetes.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit PYPD on AllInvestView.